Pharmaceuticals · VIYASH
Pharma - Animal
from 263 today
Viyash reported a beat on Q1FY27 estimates driven by a surge in the formulation business, with sustained high margins and robust growth ahead across API, CDMO, and animal health portfolios leading to a BUY rating with a target price of Rs 345.
We remain constructive on the near- to medium-term growth outlook, supported by a robust portfolio of USVMF/DMF filings and large USFDA-approved API capacities that provide a strong foundation to scale the CDMO opportunity. We tweak our estimates and maintain BUY with a Target Price of Rs. 310.
We initiate on Viyash Scientific with a BUY rating and a TP of Rs325, based on 30x Aug’28ii EPS. With multiple growth levers in formulations and API business across Human and Animal Health, along with merger synergies, we expect Viyash to deliver Revenue/Ebitda/EPS Cagr of 15/19/36% over FY26-29ii.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
